exact
ZELIRA
exact
ZELIRA
Trademarks matching 'zelira'
Summary of page content
2020-01-09
US
-
5
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
preparations for medical purposes derived from cannabis for the prevention, management and treatment of opioid addiction, cancer including breast cancer, brain cancer and pancreatic cancer, pain, chronic pain, terminal illnesses, epilepsy, arthritis, crohn's disease, insomnia, diabetes, eczema, psychiatric diseases and disorders including mood disorders, anxiety disorders, sleep disorders, cognitive disorders, alzheimer's, depression, autism and post-traumatic stress disorder; all of the foregoing containing or solely derived from hemp with a delta-9 tetrahydrocannabinol (thc) concentration of not more than 0.3 percent on a dry weight basis and not containing cbd; none of the foregoing being preparations to treat deficiencies of alpha-one proteinase inhibitors
-
42
Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software
conducting clinical trials for others; research relating to science; provision of pharmaceutical research services; project management and planning of clinical trials, namely, consulting services for others in the field of design, planning, and implementation project management of clinical trials; research relating to pharmaceuticals; research relating to medicinal use of marijuana and cannabis; scientific research relating to medicinal use of cannabis; scientific research and development of medicinal cannabis products; medical research; scientific research for medical purposes; scientific research; all of the foregoing featuring only hemp with a delta-9 tetrahydrocannabinol (thc) concentration of not more than 0.3 percent on a dry weight basis; none of the foregoing in relation to the treatment of deficiencies of alpha-one proteinase inhibitors
661
RESPONSE AFTER NON-FINAL ACTION - ENTERED
2021-03-23
2021-03-24
international life management system design advanced protein cancer corporation journal anika dental diagnostics institute precision gene sports imaging access adams